抗體生產市場規模、佔有率、成長分析、按產品、按工藝、按類型、按最終用途、按地區 - 行業預測，2024-2031 年

2022年全球抗體生產市場規模為164億美元，從2023年的185.2億美元成長到2031年的488.8億美元，在預測期內（2024-2031年）預計複合年成長率為12.9%。

由於對抗體的需求不斷增加，抗體生產市場正在經歷顯著成長，抗體對於標靶治療、診斷和疫苗至關重要。生物技術的進步和對分子疾病機制的更深入了解正在增加對用於研究和個人化醫療的特異性和有效抗體的需求。慢性病和感染疾病流行繼續推動這一需求，特別是對癌症和自體免疫疾病等治療的需求。機會比比皆是，重組 DNA 技術和高通量篩檢等創新提高了生產效率和擴充性。該市場在醫療保健行業中發揮著至關重要的作用，適應不斷變化的需求，同時推動創新和擴張，以應對日益向精準醫療的轉變。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管分析
• 案例研究分析
• 專利分析

抗體生產市場規模：依產品分類

• 市場概況
• 裝置
  • 反應器
  • 多用途反應器
  • 反應器
  • 其他
• 層析法系統
• 過濾系統
• 消耗品
  • 媒體
  • 緩衝液和試劑
  • 層析法樹脂和管柱
  • 過濾耗材及配件
  • 其他
• 軟體

抗體生產市場規模：依製程分類

• 市場概況
• 上游加工
• 下游加工

抗體生產市場規模：按類型

• 市場概況
• 多株抗體
• 單株抗體

抗體生產市場規模：依最終用途分類

• 市場概況
• 製藥和生物技術公司
• 研究室
• CROS 和 CDMOS

抗體生產市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Roche（Switzerland）
• Genmab（Denmark）
• Amgen（US）
• Biogen（US）
• Johnson & Johnson（US）
• AbbVie（US）
• AstraZeneca（UK）
• Novartis（Switzerland）
• Pfizer（US）
• Sanofi（France）
• Merck & Co.（US）
• Gilead Sciences（US）
• Celgene（US）
• BioMarin Pharmaceutical（US）
• Shire（Ireland）
• Alexion Pharmaceuticals（US）
• Teva Pharmaceuticals（Israel）
• Allergan（US）
• Bristol Myers Squibb（US）
• Novo Nordisk（Denmark）

結論和建議

Global Antibody Production Market size was valued at USD 16.4 billion in 2022 and is poised to grow from USD 18.52 billion in 2023 to USD 48.88 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2024-2031).

The antibody production market is witnessing significant growth, spurred by the rising demand for antibodies essential in targeted therapies, diagnostics, and vaccines. Advances in biotechnology and a deeper understanding of molecular disease mechanisms have heightened the need for specific and effective antibodies used in research and personalized medicine. The prevalence of chronic and infectious diseases continues to drive this demand, particularly for treatments in cancer, autoimmune disorders, and other conditions. Opportunities abound due to technological innovations, including recombinant DNA technology and high-throughput screening, which enhance production efficiency and scalability. This market plays a crucial role in the healthcare industry, adapting to evolving needs while fostering innovation and expansion in response to the increasing shift towards precision medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Production Market Segmental Analysis

Global Antibody Production Market is segmented by product, process, type, end use and region. Based on product, the market is segmented into instruments, chromatography systems, filtration systems, consumables and software. Based on process, the market is segmented into upstream processing and downstream processing. Based on type, the market is segmented into polyclonal antibody and monoclonal antibody. Based on end use, the market is segmented into pharmaceutical and biotechnology companies, research laboratories and cros and cdmos. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Production Market

The Global Antibody Production market is significantly driven by the escalating demand for antibody-based therapeutics, propelled by the rising incidence of chronic diseases and the widespread adoption of targeted treatment strategies. Antibodies are prized for their precision and effectiveness in managing a variety of health conditions, including cancer, autoimmune disorders, and infectious diseases. The emergence and application of monoclonal antibodies (mAbs) have transformed treatment modalities, leading to numerous blockbuster medications originating from antibody therapies. This increasing emphasis on specialized and efficient therapeutic options continues to bolster the market, reflecting the critical role of antibodies in modern medicine.

Restraints in the Global Antibody Production Market

The Global Antibody Production market faces significant restraints due to high development and production costs. The intricate processes involved in antibody development, coupled with extensive research and the need for expansive manufacturing facilities, lead to elevated expenses that can burden small and medium-sized enterprises. This cost-intensive nature of antibody production creates barriers to entry and diminishes the affordability and accessibility of antibody-based therapies, ultimately hampering market expansion. As a result, these economic challenges pose a substantial obstacle to growth within the industry, making it difficult for smaller players to compete and innovate in this evolving market landscape.

Market Trends of the Global Antibody Production Market

The Global Antibody Production market is witnessing a significant market trend driven by the increasing focus on personalized medicine. As healthcare systems shift towards more tailored treatment approaches, antibody production plays a pivotal role in creating targeted therapies designed to meet the unique needs of individual patients. Recent advancements in genomic and proteomic technologies have streamlined the identification of specific disease markers, enhancing the ability to design and manufacture antibodies that precisely target these markers. This alignment with personalized medicine not only fosters improved patient outcomes but also stimulates growth in the antibody production sector, as stakeholders increasingly prioritize customized therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Antibody Production Market Size by Product & CAGR (2024-2031)

• Market Overview
• Instruments
  • Bioreactors
  • Multi-Use Bioreactors
  • Single-Use Bioreactors
  • Others
• Chromatography Systems
• Filtration Systems
• Consumables
  • Media
  • Buffers and Reagents
  • Chromatography Resins and Columns
  • Filtration Consumables and Accessories
  • Others
• Software

Global Antibody Production Market Size by Process & CAGR (2024-2031)

• Market Overview
• Upstream Processing
• Downstream Processing

Global Antibody Production Market Size by Type & CAGR (2024-2031)

• Market Overview
• Polyclonal Antibody
• Monoclonal Antibody

Global Antibody Production Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Pharmaceutical and Biotechnology Companies
• Research Laboratories
• CROS and CDMOS

Global Antibody Production Market Size & CAGR (2024-2031)

• North America (Product, Process, Type, End Use)
  • USA
  • Canada
• Europe (Product, Process, Type, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Process, Type, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Process, Type, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Process, Type, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations